Cosmo脱发新药三期临床告捷；石药集团双靶点新药FDA临床批准；百奥赛图B7H3/PTK7双抗ADC获FDA批准

药财社2025-12-08

●药闻快报▲关注药财社聚焦医药界▲1Cosmo脱发新药三期临床告捷近日，Cosmo Pharmaceuticals宣布Clascoterone 5%外用溶液治疗男性雄激素性脱发（AGA）的两项III期临床试验取得积极结果。试验结果显示，Clascoterone 5%溶液在目标区域毛发计数方面达到了具有统计学意义（p<0.05）且临床意义重大的改善，其中一项研究更是实现了惊人的539%相对改善率。除...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2590505350?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-08 19:02","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2590505350","market":"hk","top_or_hot":-1,"title":"Cosmo脱发新药三期临床告捷；石药集团双靶点新药FDA临床批准；百奥赛图B7H3/PTK7双抗ADC获FDA批准","media":"药财社","content":"<div>\n<p>●药闻快报▲关注药财社聚焦医药界▲1Cosmo脱发新药三期临床告捷近日，Cosmo Pharmaceuticals宣布Clascoterone 5%外用溶液治疗男性雄激素性脱发（AGA）的两项III期临床试验取得积极结果。试验结果显示，Clascoterone 5%溶液在目标区域毛发计数方面达到了具有统计学意义（p<0.05）且临床意义重大的改善，其中一项研究更是实现了惊人的539%相对改善率。除...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208200527a72b1d02&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cosmo脱发新药三期临床告捷；石药集团双靶点新药FDA临床批准；百奥赛图B7H3/PTK7双抗ADC获FDA批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCosmo脱发新药三期临床告捷；石药集团双靶点新药FDA临床批准；百奥赛图B7H3/PTK7双抗ADC获FDA批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-08 19:02 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208200527a72b1d02&s=b><strong>药财社</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>●药闻快报▲关注药财社聚焦医药界▲1Cosmo脱发新药三期临床告捷近日，Cosmo Pharmaceuticals宣布Clascoterone 5%外用溶液治疗男性雄激素性脱发（AGA）的两项III期临床试验取得积极结果。试验结果显示，Clascoterone 5%溶液在目标区域毛发计数方面达到了具有统计学意义（p<0.05）且临床意义重大的改善，其中一项研究更是实现了惊人的539%相对改善率。除...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208200527a72b1d02&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1226287792.SGD","symbol_name":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P\" (SGDHDG) INC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208200527a72b1d02&s=b","article_id":"2590505350","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208200527a72b1d02&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2590505350","pubTimestamp":1765191720,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"2石药集团双靶点新药FDA临床批准12月5日，石药集团宣布，本集团开发的GLP-1/GIP受体双偏向性激动多肽注射液已获得美国食品药品监督管理局批准，可在美国开展临床试验。3百奥赛图B7H3/PTK7双抗ADC获FDA批准2025年12月5日，百奥赛图宣布，其合作伙伴IDEAYA 公司已获得美国FDA的临床试验用新药批准，推进同类首创B7H3/PTK7双特异性抗体偶联物项目的I期临床试验。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1226287792.SGD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P\" (SGDHDG) INC","BK1191":"制药","LU1960683339.HKD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (HKD) ACC","BK1161":"生物科技","LU0140636845.USD":"施罗德大中华区股票A Acc","LU1152091168.USD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" INC","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","LU0315179316.USD":"EASTSPRING INVESTMENTS ASIAN DYNAMIC \"A\" (USD) ACC","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","LU1328277881.USD":"MANULIFE GF DRAGON GROWTH FUND \"AA\" (USD) INC","LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","LU1152091754.HKD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" (HKD) INC","BK1515":"抗疫概念","LU0314109678.HKD":"MANULIFE GF DRAGON GROWTH \"AA\" (HKD) INC","IE0008368742.USD":"首域中国增长基金I Acc","LU1008478684.HKD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (HKD) ACC","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","IE00B031HY20.USD":"FSSA CHINA GROWTH \"I\" (USD) INC","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","01093":"石药集团","LU1226288170.HKD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P6%\"(HK D) INC","BK1521":"挪威政府全球养老基金持仓","LU1226287875.USD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"PM\" (USD) INC","LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC","LU1226288253.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) INC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","LU1951186391.HKD":"UBS (LUX) KEY SEL CHINA ALLOCATION OPPORTUNITY (US \"P\" (HKD) INC","IE0008369823.USD":"FSSA HONG KONG GROWTH \"I\" ACC","LU1813983027.USD":"MANULIFE GF DRAGON GROWTH \"AA\" (USD) INC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","02315":"百奥赛图-B"},"translate_title":"Cosmo's new hair loss drug was successful in phase III clinical trial; CSPC's dual-target new drug FDA clinical approval; Biocytol B7H3/PTK7 double antibody ADC approved by FDA","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1.5,"02315":0.9},"content_text":"●药闻快报▲关注药财社聚焦医药界▲1Cosmo脱发新药三期临床告捷近日，Cosmo Pharmaceuticals宣布Clascoterone 5%外用溶液治疗男性雄激素性脱发（AGA）的两项III期临床试验取得积极结果。试验结果显示，Clascoterone 5%溶液在目标区域毛发计数方面达到了具有统计学意义（p<0.05）且临床意义重大的改善，其中一项研究更是实现了惊人的539%相对改善率。除客观指标外，患者自我报告结果（PROs）进一步印证了疗效，其中一项研究的PRO终点达到统计学显著性，另一项显示积极趋势，联合分析结果与TAHC测量高度一致，证实患者切实感受到了有意义的改善。在安全性方面，该药物展现出积极特征，治疗中出现的不良事件（TEAE）与安慰剂组相似，且大多数事件与研究药物无关。Clascoterone的颠覆性在于其独特的作用机制。作为首个专为AGA开发的局部雄激素受体抑制剂，它能直接在毛囊受体处阻断二氢睾酮（DHT），这一导致男性脱发的生物学根源，且无需全身吸收即可起效。这种精准定位的策略，使其在避免口服疗法（如非那雄胺）相关全身性激素风险的前提下，实现了真实可测量的毛发再生。2石药集团双靶点新药FDA临床批准12月5日，石药集团宣布，本集团开发的GLP-1/GIP受体双偏向性激动多肽注射液（SYH2069注射液）已获得美国食品药品监督管理局(FDA)批准，可在美国开展临床试验。该产品有望成为中国首款进入临床阶段的GLP-1/GIP受体双偏向激动剂，可选择性激活cAMP通路，显著降低β-arrestin募集，从而减少受体内吞及脱敏，提高药效和效果持续性。同时，结合长半衰期修饰平台技术，该产品能实现更深度、更持久的减重效果。在饮食诱导肥胖(DIO)小鼠和非人灵长类的研究中，该产品在减重及代谢改善方面的效果均显著优于同类上市产品。非人灵长类重复给药毒理研究显示，该产品耐受性良好，未观察到任何呕吐及胃肠道不良反应。该产品具备出色的药效及良好的安全性，有望成为超重/肥胖及其他代谢类疾病的新一代疗法。3百奥赛图B7H3/PTK7双抗ADC获FDA批准2025年12月5日，百奥赛图宣布，其合作伙伴IDEAYA 公司已获得美国FDA的临床试验用新药（IND）批准，推进同类首创B7H3/PTK7双特异性抗体偶联物（ADC）项目的I期临床试验。IDEAYA预计将在2026年第一季度开始患者入组，初步评估B7H3和PTK7共表达的实体瘤类型，包括肺癌、结直肠癌、头颈癌及卵巢/妇科肿瘤。IDE034是是百奥赛图自主开发的一款潜在同类首创（first-in-class）的双靶点B7H3/PTK7 TOP1 ADC。2024年7月，百奥赛图将该双靶点ADC项目以总价值4 亿美元授权给 IDEAYA 公司，推动全球开发与商业化。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590505350","isCrawlerRequest":true}